On June 28, Layn Biology announced in a press release that its subsidiary, Holding, had used its own funds to subscribe to 4,907,590 shares of common stock from Ispire's targeted issuance of unlimited shares. The subscription price was $7.1318 per share. As of now, the targeted issuance by Ispire has been completed, and Layn Biology now holds a total of 705,044 shares in Ispire.
On February 20, 2023, Layn Biotech and its subsidiary invested up to 50 million yuan (RMB) in securities using their own funds. On April 4, 2023 (US time), Layn Biotech's wholly-owned subsidiary, Holding, used approximately 1.5 million US dollars of its own funds to acquire 214,285 shares of Ispire through its initial public offering on the NASDAQ stock exchange at a price of $7.00 per share.
Ispire is a company registered in the United States specializes in the research, design, and sales of e-cigarettes and vaporization products related to cannabis, including industrial hemp.
References:
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
